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OBJECTIVES We sought to evaluate the efficacy of abciximab as adjunctive therapy to routine infarct-
related artery (IRA) stenting.
BACKGROUND The impact of abciximab on the efficacy of myocardial reperfusion and the outcome of
patients with acute myocardial infarction (AMI) undergoing IRA stenting have not yet been
defined.
METHODS In a randomized trial, we assigned 400 patients with AMI to undergo IRA stenting alone or
stenting plus abciximab. The primary end point was a composite of death, reinfarction, target
vessel revascularization (TVR), and stroke at one month.
RESULTS The incidence of the primary end point was lower in the abciximab group than in the stent
only group (4.5% and 10.5%, respectively; p  0.023), and randomization to abciximab was
independently related to the risk of the primary end point (odds ratio 0.41, 95% confidence
interval 0.17 to 0.97; p  0.041). Early ST-segment resolution was more frequent in the
abciximab group (85% vs. 68%, p  0.001). Infarct size, as assessed by one-month
technetium-99m sestamibi scintigraphy, revealed smaller infarcts in the abciximab group. At
six months, the cumulative difference in mortality between the groups increased (4.5% vs.
8%), and the incidence of the composite of six-month death and reinfarction was lower in the
abciximab group than in the stent only group (5.5% and 13.5%, respectively; p  0.006).
Six-month repeat TVR and restenosis rates were similar in the two groups.
CONCLUSIONS Abciximab plus IRA stenting should be considered the routine reperfusion strategy in patients
with AMI undergoing primary percutaneous mechanical revascularization, especially in
high-risk patients. (J Am Coll Cardiol 2003;42:1879–85) © 2003 by the American College
of Cardiology Foundation
Several studies comparing primary coronary angioplasty
with primary stenting for acute myocardial infarction (AMI)
have shown that primary stenting improves the procedural
success rate and clinical outcome (1–6). The impact of
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abciximab as adjunctive therapy to stenting on the efficacy of
myocardial reperfusion and the outcome of patients with
AMI have not yet been defined, and three completed
randomized trials comparing stenting alone with stenting
plus abciximab have produced conflicting results (6–8).
Differences in the criteria used for patient recruitment and
in adjunctive pharmacologic treatments may partly explain
these discrepancies and prevent the generalizability of the
concluded trial results to all patients with AMI. We
therefore conducted an international, multicenter random-
ized trial to determine the impact of abciximab on the
clinical outcome of patients with ST-segment elevation
AMI undergoing routine infarct-related artery (IRA) stent-
ing. We used broad inclusion criteria, and patients were
enrolled without any restriction based on age, the risk of
clinical status on presentation, and the risk of coronary
anatomy, in order to have an enrolled population represen-
tative of the “real world” of patients with AMI.
METHODS
Study population and protocol. The study was conducted
from January 2001 to August 2002. Criteria for enrollment
included: 1) chest pain persisting more than 30 min and
associated with ST-segment elevation of at least 0.1 mV in
two or more contiguous electrocardiographic (ECG) leads;
and 2) admission either within 6 h of symptom onset or
between 6 and 24 h if there was evidence of continuing
From the *Division of Cardiology, Careggi Hospital, Florence, Italy; †Invasive
Cardiology Department, Otamendi Hospital, Buenos Aires, Argentina; ‡Bernau
Heart Center, Bernau, Germany; §Cardiology Department, Monzino Hospital,
Milan, Italy; and Centro Cuore Columbus, Columbus Hospital, Milan, Italy. This
study was presented, in part, at the Transcatheter Cardiovascular Therapeutics
Session in Washington, DC, September 2002, and at the 50th Annual Session of the
American College of Cardiology, Chicago, Illinois, March 2003. This study was
supported by SORIN Biomedica and the ARCARD ONLUS Foundation.
Manuscript received August 6, 2003; revised manuscript received July 8, 2003,
accepted July 10, 2003.
Journal of the American College of Cardiology Vol. 42, No. 11, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.07.017
ischemia. Patients with cardiogenic shock (CS) due to
predominant ventricular failure were included. Cardiogenic
shock due to predominant ventricular failure was defined as
systolic blood pressure 90 mm Hg (without inotropic or
intra-aortic balloon support) that was thought to be second-
ary to ventricular dysfunction and associated with signs of
end-organ hypoperfusion such as: cold or diaphoretic ex-
tremities; altered mental status; or anuria. The exclusion
criteria included previous administration of fibrinolytic or
abciximab therapy, a history of bleeding diathesis or allergy
to the study drug, major surgery within 15 days, active
bleeding, participation in another study, and inability to
obtain informed consent. All patients with a reference IRA
diameter 2.5 mm were eligible for stenting and random-
ization. Unlike in previous studies, evidence of massive
coronary thrombus, diffuse disease, a major branch involved
in the culprit lesion, left main coronary disease, or severe
vessel tortuosity were not considered contraindications to
stenting. Angiographic criteria for exclusion from random-
ization included: 1) IRA reference diameter 2.5 mm on
visual assessment at baseline angiography; 2) a previously
stented IRA; 3) 70% stenosis of the IRA associated with
Thrombolysis In Myocardial Infarction (TIMI) trial flow
grade 3 (9); and 4) an inability to identify the IRA.
Before catheterization, patients received 325 mg aspirin
orally or 250 mg intravenously.
After coronary angiography, patients were randomly as-
signed to stenting alone or stenting plus abciximab. Ran-
domization was carried out by means of a computer-
generated sequence, and assignments were made using a
centralized telephone system. Data on nonrandomized pa-
tients were collected in a parallel registry.
Coronary stenting had to be attempted with a carbofilm-
coated tubular stent (Carbostent, SORIN, Saluggia, Italy).
Crossover to other types of stent was allowed only after
failure of a Carbostent implantation attempt. Coronary
stenting was accomplished using a standard technique or
directly, without predilation, at the discretion of the oper-
ator. Patients randomized to abciximab (ReoPro, Centocor,
Malvern, Pennsylvania) received the drug immediately be-
fore the procedure as a bolus of 0.25 mg/kg body weight,
followed by a 12-h infusion at a rate of 0.125 g/kg/min.
Heparin was given as an initial bolus of 70 U/kg, and
additional boluses were administered during the procedure
to achieve an activated clotting time of 200 to 300 s among
the patients assigned to receive abciximab and at least 300 s
in patients assigned to stenting alone. In the group of
patients who were assigned to stenting alone, crossover to
abciximab was strongly discouraged. In patients receiving
abciximab, heparin was continued for 12 h, whereas in the
remaining patients, intravenous heparin was continued for
two days after the procedure. Immediately after the proce-
dure, patients received 500 mg ticlopidine or 300 mg
clopidogrel. Patients were routinely treated with aspirin
(325 mg/day indefinitely), and either ticlopidine (500 mg/
day for 1 month) or clopidogrel (75 mg/day for 1 month).
Coronary angiography was required for all eligible pa-
tients six months after the procedure. Quantitative coronary
angiography included the assessment of TIMI flow grade,
corrected TIMI frame count, IRA reference diameter,
minimum lumen diameter, and reference and minimum
lumen diameters at six months. These quantitative angio-
graphic parameters were assessed as previously described
(9–11).
A 12-lead ECG was recorded continuously 30 min after
IRA recanalization. The ST-segment changes were evalu-
ated in the single lead with the most prominent ST-
segment elevation before mechanical intervention. ST-
segment elevation was measured to the nearest 0.5 mm at 60
ms after the J point, with the aid of hand-held calipers.
According to a previous report (12), a reduction in ST-
segment elevation was defined as a decrease of 50% in
ST-segment elevation at 30 min after IRA recanalization.
Creatine kinase (CK) measurements were systematically
performed on hospital admission, every 3 h for the subsequent
24 h, and then every 12 h for two days. The peak CK value and
the time to peak CK were estimated for each patient.
A technetium-99m (99mTc)-sestamibi scintigram for de-
termination of infarct size at one month, as previously
described (13), was pre-specified in a subgroup of 250
consecutive patients.
Independent analyses of the ECGs, scintigrams, and
coronary angiograms were performed at ECG, nuclear
medicine, and angiographic core laboratories whose mem-
bers were unaware of patient treatment assignment and
clinical outcome.
End points. The primary end point was a composite of
death from any cause, reinfarction, target vessel revascular-
ization (TVR), and stroke within one month of the index
procedure. Patients with more than one event were assigned
the highest ranked event, according to the previous list. The
secondary end points were ST-segment reduction, postpro-
cedural corrected TIMI frame count, infarct size at one
month, death from any cause at six months, reinfarction at
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six months, six-month composite of death and reinfarction,
TVR at six months, and angiographic restenosis of the IRA
at six months. “Reinfarction” was defined as recurrent chest
pain with ST-segment or T-wave changes and recurrent
elevation of cardiac enzymes. “Repeat TVR” was defined as
coronary angioplasty or coronary surgery performed due to
restenosis or reocclusion of the IRA. “Stroke” was defined as
an acute neurologic defect that lasted more than 24 h and
resulted in death or an inability to perform normal activities.
Statistical analysis. The sample size was calculated on the
assumption that the primary end point would occur in 13%
of patients randomized to stenting alone and in 5% of
patients randomized to stenting plus abciximab. To detect a
difference with 80% power and a type I error (alpha) of 0.05,
198 patients per group were required. Discrete data are
summarized as frequencies, whereas continuous data are
expressed as median values and interquartile ranges. The
chi-squared test was used for comparison of categorical
variables. The Mann-Whitney U test was used to test
differences among continuous variables. Survival curves were
generated using the Kaplan-Meier method, and the differ-
ence between curves was assessed by the log-rank test.
Forward stepwise multivariate logistic regression analysis
was performed to identify independent correlates of the
primary end point, six-month mortality, and cumulative
six-month mortality and reinfarction. The factors analyzed
included age (years), gender, diabetes mellitus, hyperten-
sion, anterior AMI, previous myocardial infarction, history
of angina, CS, multivessel disease, preprocedural TIMI flow
grade 1, Rentrop collateral flow grade 1 (14), primary
failure, time from symptom onset to recanalization (hours),
randomization to abciximab, and stent length 20 mm. All
analyses were conducted according to the intention-to-treat
principle. A p value0.05 was considered significant. Odds
ratios (ORs) with 95% confidence intervals (CIs) were
calculated. Analyses were performed using the package
software SPSS version 8.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Patient population. A total of 485 patients with ST-
segment elevation AMI were admitted to four centers in
three countries, 400 (82%) of whom underwent randomiza-
tion. The reasons for exclusion of 85 patients from random-
Table 1. Baseline Characteristics of the Patients
Stenting Alone Group
(n  200)
Stenting Plus
Abciximab Group
(n  200) p Value
Age (yrs)
Median 63 64 0.473
Interquartile range 53–74 55–74
Range 32–90 36–90
Male 157 (79%) 152 (76%) 0.551
Hypertension 94 (47%) 92 (46%) 0.841
Hypercholesterolemia 78 (39%) 80 (40%) 0.838
History of smoking 82 (41%) 78 (39%) 0.683
Diabetes mellitus 37 (19%) 33 (17%) 0.699
Previous myocardial infarction 25 (12%) 20 (10%) 0.279
Previous coronary angioplasty 11 (6%) 7 (4%) 0.335
Previous coronary surgery 6 (3%) 4 (2%) 0.522
Anterior AMI 92 (46%) 81 (40%) 0.267
Cardiogenic shock 21 (10%) 16 (8%) 0.388
Not-low-risk patients 134 (67%) 129 (65%) 0.588
Symptom onset to reperfusion (h)
Median 4.17 3.73 0.080
Interquartile range 3.1–5.5 2.9–5.5
Infarct-related artery (%) 0.453
LAD 91 (45%) 79 (40%)
RCA 74 (37%) 89 (44%)
LCx 33 (17%) 31 (15%)
LMCA 2 (1%) 1 (0.5%)
TIMI flow grade 0–1 149 (75%) 156 (78%) 0.411
Multivessel disease 115 (57%) 108 (54%) 0.481
Collateral flow grade 2 17 (8%) 12 (6%) 0.335
Reference infarct artery diameter (mm)
Median 3.13 3.18 0.624
Interquartile range 2.88–3.53 2.91–3.49
Minimal lumen diameter (mm)
Median 0 0 0.974
Interquartile range 0–0.48 0–0.46
Data are presented as the number (%) of patients, unless otherwise specified.
AMI  acute myocardial infarction; LAD  left anterior descending coronary artery; LCx  left circumflex artery; LMCA
 left main coronary artery; RCA  right coronary artery; TIMI  Thrombolysis in Myocardial Infarction trial.
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ization were IRA diameter 2.5 mm (n  15), contrain-
dication to abciximab treatment (n  25), moribund state
on admission (n  8), previous IRA stenting (n  8),
abciximab treatment before admission (n  8), and an
inability to obtain informed consent (n  21).
Table 1 summarizes the baseline characteristics of ran-
domized patients. The two groups were well matched in
terms of all baseline characteristics, and the majority of the
patients were “not low risk,” according to the TIMI criteria
(15).
In-hospital therapy. Table 2 summarizes the procedural
characteristics and results. All patients randomized to ab-
ciximab had abciximab treatment, and crossover to abcix-
imab occurred in 22 patients (11%) of the stent only group.
Overall, there were three primary angioplasty failures.
Stenting of the IRA was accomplished in 99% of patients
using the study stent, and no crossover to other types of
stent occurred in patients with an unsuccessful Carbostent
implantation attempt.
Primary end point. The incidence of the primary end
point was lower in the abciximab group than in the stent
only group (4.5% and 10.5%, respectively; p  0.023)
(Table 3, Fig. 1). Each of the components of the primary
end point was lower in the abciximab group, and the
difference in the incidence of the primary end point was
mostly due to the lower incidence of reinfarction. Early
target vessel failure occurred in 14 patients and resulted in
reinfarction in 10, despite repeat successful emergency
revascularization. Coronary angiography revealed stent
thrombosis in 11 patients and post-stent dissection in three.
Stent thrombosis was detected in all but one patient who
developed reinfarction. All patients with stent thrombosis
had one or more of the following unfavorable clinical and
procedural characteristics: multiple stents (n  5), diabetes
(n 5), CS (n 3), crossover to bailout abciximab (n 3),
and final inflation pressure 18 atm (n  6). By multivar-
iate analysis, the independent predictors of the primary end
point were age (OR 1.03, 95% CI 1.00 to 1.07; p  0.031),
multivessel disease (OR 3.02, 95% CI 1.15 to 7.93; p 
0.025), CS (OR 7.53, 95% CI 3.12 to 18.14; p  0.001),
and randomization to abciximab (OR 0.41, 95% CI 0.17 to
0.97; p  0.041).
Secondary end points. ST-segment reduction was more
frequent in the abciximab group (Table 3). There were no
differences in the postprocedural corrected TIMI frame
count between the groups (Table 3).
Infarct size, as assessed by one-month 99mTc-sestamibi
scintigraphy, revealed smaller infarcts in the abciximab
group (Table 3). This difference was more evident in the
subset of patient with ST-segment reduction. Moreover,
patients with no detectable scintigraphic defect at one
month were more frequently included in the abciximab
group.
At six months, the cumulative difference in mortality
between groups increased, with a 44% reduction in the
abciximab groups (4.5% vs. 8.0%, p  0.148), whereas the
difference in the incidence of reinfarction was maintained.
The incidence of the composite of six-month death or
reinfarction was lower in the abciximab group than in the
stent only group (5.5% and 13.5%, respectively; p  0.006)
(Fig. 2A). By multivariate analysis, the independent predic-
tors of six-month mortality or reinfarction were age (OR
1.04, 95% CI 1.01 to 1.08; p  0.014), CS (OR 7.85, 95%
CI 3.21 to 19.16; p  0.001), ST-segment reduction (OR
0.34, 95% CI 0.15 to 0.76; p  0.009), and randomization
to abciximab (OR 0.40, 95% CI 0.17 to 0.93; p  0.033).
The six-month mortality rate was 3.4% in the subset of
patients with ST-segment reduction (10 of 294 patients)
and 16% in the subset of patients without ST-segment
reduction (14 of 88 patients) (Fig. 2B). The ST-segment
reduction was independently related to six-month mortality
(OR 0.31, 95% CI 0.12 to 0.81; p  0.016).
Rates of repeat TVR and restenosis were similar in the
two groups.
Bleeding and vascular complications. There were no
differences in hemorrhagic complications requiring blood
transfusion or vascular repair between the groups (3.5% vs.
3.0%, p  0.778). There were no hemorrhagic strokes (a
computed tomographic scan showed that the only disabling
stroke was nonhemorrhagic).
Table 2. Procedural Characteristics and Results
Stenting
Alone
Group
(n  200)
Stenting Plus
Abciximab
Group
(n  200)
p
Value
Primary failure 2 (1%) 1 (0.5%) 0.511
Infarct artery stenting 197 (99%) 198 (99%) 0.653
Stent type
Carbostent 197 198
Others 0 0
Multiple stents 55 (27%) 47 (23%) 0.359
Stent length (mm)
Median 19 15 0.266
Interquartile range 12–24 12–25
Abciximab administration 22 (11%) 200 (100%) 0.001
Intra-aortic balloon
counterpulsation
21 (10%) 15 (7.5%) 0.295
Final TIMI flow grade 3 192 (96%) 194 (97%) 0.719
Final minimal lumen
diameter (mm)
Median 2.86 2.87 0.974
Interquartile range 2.54–3.15 2.45–3.20
Final stenosis (%)
Median 10 10 0.117
Interquartile range 3–12 5–17
Peak CK median value 111 (57%) 89 (45%) 0.018
Time to peak CK (h)
Median 14.12 10.08 0.001
Interquartile range 11.0–16.0 8.5–12.5
6 h 60 (31%) 139 (70%) 0.001
Data are presented as the number (%) of patients, unless otherwise specified.
CK  creatine kinase; TIMI  Thrombolysis In Myocardial Infarction.
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DISCUSSION
The results of this trial show that abciximab provides a
better clinical outcome than stenting alone in patients with
ST-segment elevation AMI. The use of abciximab reduced
the rate of the one-month composite of death, reinfarction,
TVR, and stroke. At six months, the reduction in mortality
increased, resulting in a significant reduction in the com-
posite of death and reinfarction. These effects are likely
related to the reduction in the subacute stent thrombosis
rate and to more effective reperfusion at the tissue level, as
shown by the more frequent ST-segment resolution in the
abciximab-treated patients and the smaller infarcts at one-
month scintigraphy. There were no differences in the
corrected TIMI frame count between the groups. This lack
of difference may be explained by the fact that assessment of
this marker of reperfusion was done immediately after the
procedure, when microvascular function might be not com-
pletely restored (16). Consistent with the results of previous
studies (6,7), there was no evidence of an abciximab effect
on six-month angiographic restenosis and TVR rates.
The results of three earlier randomized trials comparing
stenting alone and stenting plus abciximab are conflicting.
Table 3. End Points
Stenting
Alone Group
(n  200)
Stenting Plus
Abciximab Group
(n  200) p Value
Primary end point
Death at 30 days 8 (4%) 7 (3.5%) 0.792
Reinfarction at 30 days 9 (4.5%) 1 (0.5%) 0.010
Target vessel revascularization at 30 days 3 (1.5%) 1 (0.5%) 0.315
Stroke 1 (0.5%) 0 0.317
Composite 21 (10.5%) 9 (4.5%) 0.023
Secondary end points
ST-segment reduction 50% at 30 min (n  188) (n  194)
129 (68%) 165 (85%) 0.001
Corrected TIMI frame count (frames) (n  193) (n  194)
Median 25.00 27.17 0.697
Interquartile range 19.18–31.75 18.78–32.80
Infarct size (n  107) (n  121)
Median 16.60 12.50 0.067
Interquartile range 6.5–26.1 3.0–24.9
No detectable defect 9 (8.4%) 22 (18%) 0.032
ST-segment reduction 50% (n  58) (n  95)
Median 18.25 11.1 0.007
Interquartile range 11.7–24.4 1.6–22.6
Death at 6 months (cumulative) 16 (8.0%) 9 (4.5%) 0.148
Causes of death
Free wall rupture 3 3
Heart failure 10 5
Reinfarction 1 0
Arrhythmia 1 1
Stroke 1 0
Reinfarction at 6 months (cumulative) 11 (5.5%) 2 (1%) 0.011
Composite of death and reinfarction at
6 months
27 (13.5%) 11 (5.5%) 0.006
Target vessel revascularization at 6 months
(cumulative)
34 (17%) 32 (16%) 0.789
Six-month angiography 138 (83%) 157 (86%) 0.338
Stenosis at 6 months
Median 30.77 23.87 0.065
Interquartile range 15.30–54.22 11.23–42.46
Stenosis 50% 39 (28%) 33 (21%) 0.149
Data are presented as the number (%) of patients, unless otherwise specified.
TIMI  Thrombolysis In Myocardial Infarction.
Figure 1. Kaplan-Meier curves for the primary end point in the abciximab
group and the stenting only group.
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The Intracoronary Stenting and Antithrombotic Regimen
(ISAR)-2 trial, based on a sample of 401 patients, showed
a benefit of abciximab in terms of a reduction in the
composite of death, reinfarction, and TVR at one month
(5.0% vs. 10.5%, p  0.038), but this benefit was no longer
evident at 12 months (7). The Abciximab before Direct
angioplasty and stenting in Myocardial Infarction Regard-
ing Acute and Long-term follow-up (ADMIRAL) trial,
based on a sample of 300 patients, showed a significant
reduction in the composite of death, reinfarction, and
urgent TVR at one month, and this benefit was maintained
at six months (7.4% vs. 15.9%, p  0.02) (8). Finally, the
Controlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications (CADILLAC) trial, based
on a sample of 2,082 patients, compared angioplasty with
stenting, with or without abciximab. The primary end point
of the study was the composite of six-month mortality,
reinfarction, TVR, and disabling stroke. The study showed
a strong benefit of coronary stenting, as compared with
coronary angioplasty, with or without abciximab, and no
adjunctive benefit of abciximab in the stenting arm (primary
end point rate 11.5% in the stenting only group [n  512]
and 10.2% in the stenting plus abciximab group [n  524])
(6). It might be hypothesized that the lack of effect of
abciximab in the stenting arm of the CADILLAC trial was
due to the very early administration of ticlopidine or
clopidogrel.
Major differences in study designs prevent a direct com-
parison of the results of our study with those of earlier trials.
We did not use stringent quantitative criteria for definition
of reinfarction, as in CADILLAC trial (CK 50% higher
than the previous values obtained during hospitalization).
However, in all cases of reinfarction, the diagnosis was
based on recurrence of chest pain, CK re-elevation, and
evidence of occlusive thrombosis or dissection of the target
vessel. Moreover, several features of our trial should be
highlighted to put the results of the study into proper
perspective. In our study, more than one-third of patients
were over 70 years old; 66% were “not low risk”; the more
frequent location of the AMI was anterior; diffuse disease or
multiple lesions within the IRA resulted in multiple stent
implantation in 25% of patients; and patients with CS on
admission were included, as well as patients with coronary
anatomy at high risk. The inclusion of high-risk patients
who were poorly represented or excluded from previous
trials may explain the positive study results, because it may
be very difficult or even impossible to show the efficacy of
treatment in low-risk patients. Moreover, the overall com-
pliance with the protocol was excellent: coronary stenting
was attempted in all patients and, in nearly all cases, was
successful when using a last-generation passive coating
stent, although the incidence of crossover to bailout abcix-
imab in patients randomized to stenting alone was very low.
The study design resulted in the enrollment of a population
whose characteristics are consistent with those of large
survey studies on AMI (17,18). Thus, the study sample can
be considered representative of the entire population of
patients with ST-segment elevation AMI. As a conse-
quence, the study results, showing a strong benefit of
abciximab as adjunctive treatment to coronary stenting, are
applicable to the generality of patients undergoing primary
stenting for ST-segment elevation AMI.
Study limitations. This study was not blinded. However,
for the component of the primary end point of TVR, the
need for reintervention was recurrent ischemia due to stent
thrombosis or dissection revealed on the emergency angio-
gram. Thus, the potential bias in the need for emergency
TVR was avoided in all cases.
Another potential limitation of the study is the different
duration of postprocedural heparin treatment in the two
arms. The rationale for this different duration is based on
the fact that platelet inhibition may be considered com-
pleted within 12 h with abciximab treatment, whereas it
needs at least 48 h with ticlopidine alone.
Reprint requests and correspondence: Dr. David Antoniucci,
Head, Division of Cardiology, Careggi Hospital, Viale Morgagni,
I-50134, Florence, Italy. E-mail: carddept@tin.it.
Figure 2. (A) Kaplan-Meier curves for the composite of death and
reinfarction at six months in the abciximab group and the stenting only
group. (B) Kaplan-Meier curves for six-month mortality in patients with
and without ST-segment reduction.
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APPENDIX
The following investigators and institutions participated in
the Abciximab and Carbostent Evaluation (ACE) trial:
Steering Committee: D. Antoniucci (Chairman), A. Rodri-
guez, A. Hempel, A. Bartorelli, A. Colombo; Data Moni-
toring (ARCARD Foundation, Careggi Hospital, Flo-
rence): E. V. Dovellini (Director), G. Cerisano, P.
Buonamici; Electrocardiographic Core Laboratory (Division of
Cardiology, Careggi Hospital, Florence): A. Migliorini
(Director); Nuclear Medicine Core Laboratory (Nuclear Med-
icine Institute, University of Florence): A. Pupi (Director);
Angiographic Core Laboratory (Milan Cardiovascular Re-
search Foundation): C. Di Mario (Director).
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